Evofem Biosciences Inc. (EVFM-OTCQB)

evofem logo

Evofem Biosciences, Inc.
7770 Regents Road, Suite 113-618
San Diego, CA 92122
Phone: (858) 550-1900

You Might Also Like...

Evofem Biosciences, Inc. (“Evofem” or “the Company”) is a commercial-stage biopharmaceutical company focused on addressing unmet needs within the women’s sexual and reproductive healthcare markets. The Company’s initial Food and Drug Administration (FDA)-approved product, Phexxi®, is a hormone-free, on-demand prescription contraceptive vaginal gel. Packaged in boxes containing twelve pre-filled applicators (like a tampon), Phexxi is inserted within one hour before intercourse and works to prevent pregnancy by maintaining the vaginal pH, which reduces sperm motility and lowers the chance of sperm reaching the egg. Evofem’s Phexxi has no systemic activity in the body, which is important to the 23 million women who are beyond using contraceptives containing hormones due to the pervasive side effects or risk of drug-drug interactions. These include women who may be breastfeeding or breast cancer patients/survivors, as well as those using GLP-1s for weight loss who need supplemental birth control because oral contraceptive pills are less effective at certain times of the GLP-1 dosing regimen. Evofem’s common stock trades on the OTCQB Venture Market under the ticker symbol "EVFM."

* Updated on May 13, 2024.

Initiation Report

Evofem Cover Page_

New Updates

Unlocking Visibility: Trusted Research by Wall Street Veterans